Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.27 USD | -2.73% | -4.23% | -34.48% |
May. 09 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
May. 09 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.48% | 911M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+49.62% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
+24.01% | 12.1B |
- Stock Market
- Equities
- VRDN Stock
- News Viridian Therapeutics, Inc.
- Transcript : Viridian Therapeutics, Inc., Q4 2022 Earnings Call, Mar 08, 2023